• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Acetamide, N-[3-(1-piperazinyl)propyl]- (CAS No. 141516-23-6): A Comprehensive Overview

Acetamide, N-[3-(1-piperazinyl)propyl]- (CAS No. 141516-23-6) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as N-[3-(1-piperazinyl)propyl]acetamide, is characterized by its unique structure, which combines an acetamide moiety with a piperazine ring linked through a propyl chain. This structural configuration imparts specific chemical and biological properties that make it a valuable candidate for various applications, particularly in drug discovery and development.

The piperazine ring is a common structural motif in many pharmaceuticals due to its ability to modulate the activity of various receptors and enzymes. In the case of N-[3-(1-piperazinyl)propyl]acetamide, the presence of this ring enhances its potential as a ligand for G protein-coupled receptors (GPCRs) and ion channels. Recent studies have shown that compounds with similar structures exhibit potent activity against a range of targets, including serotonin receptors, dopamine receptors, and calcium channels.

One of the key areas of research involving N-[3-(1-piperazinyl)propyl]acetamide is its potential as an anticonvulsant agent. Preclinical studies have demonstrated that this compound can effectively reduce seizure activity in animal models of epilepsy. The mechanism of action is thought to involve the modulation of voltage-gated sodium channels and the enhancement of GABAergic neurotransmission. These findings suggest that N-[3-(1-piperazinyl)propyl]acetamide could be a promising lead compound for the development of novel anticonvulsant drugs.

In addition to its anticonvulsant properties, N-[3-(1-piperazinyl)propyl]acetamide has also been investigated for its potential as an antidepressant and anxiolytic agent. Studies have shown that this compound can increase serotonin and norepinephrine levels in the brain, which are neurotransmitters known to play crucial roles in mood regulation. The ability to modulate these neurotransmitter systems makes N-[3-(1-piperazinyl)propyl]acetamide a potential candidate for treating mood disorders such as depression and anxiety.

The pharmacokinetic properties of N-[3-(1-piperazinyl)propyl]acetamide have also been extensively studied. Research has shown that this compound exhibits good oral bioavailability and favorable pharmacokinetic profiles, which are essential for its use as a therapeutic agent. The compound is rapidly absorbed from the gastrointestinal tract and has a moderate half-life, allowing for once-daily dosing regimens in preclinical models.

Furthermore, N-[3-(1-piperazinyl)propyl]acetamide has demonstrated low toxicity in preclinical studies, which is a critical factor for its potential clinical application. Toxicity assessments have shown that this compound does not cause significant adverse effects at therapeutic doses, making it a safe candidate for further development.

The synthesis of N-[3-(1-piperazinyl)propyl]acetamide involves several well-established chemical reactions. One common synthetic route involves the reaction of 3-chloropropionitrile with piperazine to form the intermediate 3-(1-piperazinyl)propionitrile, followed by hydrolysis to yield the final acetamide product. This synthetic pathway is efficient and scalable, making it suitable for large-scale production.

In conclusion, Acetamide, N-[3-(1-piperazinyl)propyl]- (CAS No. 141516-23-6) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and favorable biological properties make it an attractive candidate for further investigation and development as a therapeutic agent. Ongoing research continues to explore its mechanisms of action and potential clinical applications, contributing to the advancement of drug discovery in various therapeutic areas.

• 141516-24-7(1-(4-(3-Aminopropyl)piperazin-1-yl)ethanone)
• 61903-11-5(1-(1,4-diazepan-1-yl)ethan-1-one)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)